Serum tryptase levels in melanoma patients

case-control study and review of the literature

Giovanni Paolino, Elisa Moliterni, Dario Didona, Michele Cardone, Teresa Lopez, Valentina Garelli, Antonio G Richetta, Ugo Bottoni, Carmen Cantisani, Alfredo Rossi, Stefano Calvieri

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Serum tryptase results from the constant release of the enzyme from mast cells and serum tryptase levels are commonly considered to be related to the total number of mast cells. They are increased in several malignancies, as pancreatic carcinoma, angiosarcoma, hepatic carcinoma and proliferative and/or non- proliferative hematological disorders. Contrariwise, it has been reported that the number of tryptase+ and chymase+ mast cells was lower in deeply invasive melanoma compared to in-situ melanoma and dysplastic nevi. Considering the underlying pathophysiological linkages between mast cells and melanocytes and that serum tryptase is related to angiogenesis, tissue-degrading proprieties and metastatization, we have decided to evaluate serum tryptase levels in melanoma patients and in a healthy control.

METHODS: We performed a case-control study evaluating serum tryptase in melanoma and in healthy group. Starting from an initial general analysis, we have performed a sub-analysis for each sample.

RESULTS: In general population serum tryptase was statistically higher in elderly patients. Generally, in melanoma patients, median serum tryptase was in lower normal range. We found a decreasing of serum tryptase levels from the healthy control to thin (≤ 1.00 mm Breslow thickness), reaching the lowest levels in thicker melanoma (≥ 1.01 m Breslow thickness), in ulcerated and metastatic melanoma.

CONCLUSION: Tryptase may have a protective role in melanoma or, conversely, it may play a role in the early stage of the tumorigenesis. Serum tryptase is an easy and useful biomarker to better investigate melanoma biology.

Original languageEnglish
JournalGiornale Italiano di Dermatologia e Venereologia
DOIs
Publication statusE-pub ahead of print - Jan 12 2017

Fingerprint

Tryptases
Case-Control Studies
Melanoma
Serum
Mast Cells
Dysplastic Nevus Syndrome
Chymases
Hemangiosarcoma
Melanocytes
Carcinogenesis
Reference Values
Biomarkers

Cite this

Serum tryptase levels in melanoma patients : case-control study and review of the literature. / Paolino, Giovanni; Moliterni, Elisa; Didona, Dario; Cardone, Michele; Lopez, Teresa; Garelli, Valentina; Richetta, Antonio G; Bottoni, Ugo; Cantisani, Carmen; Rossi, Alfredo; Calvieri, Stefano.

In: Giornale Italiano di Dermatologia e Venereologia, 12.01.2017.

Research output: Contribution to journalArticle

Paolino, G, Moliterni, E, Didona, D, Cardone, M, Lopez, T, Garelli, V, Richetta, AG, Bottoni, U, Cantisani, C, Rossi, A & Calvieri, S 2017, 'Serum tryptase levels in melanoma patients: case-control study and review of the literature', Giornale Italiano di Dermatologia e Venereologia. https://doi.org/10.23736/S0392-0488.17.05524-9
Paolino, Giovanni ; Moliterni, Elisa ; Didona, Dario ; Cardone, Michele ; Lopez, Teresa ; Garelli, Valentina ; Richetta, Antonio G ; Bottoni, Ugo ; Cantisani, Carmen ; Rossi, Alfredo ; Calvieri, Stefano. / Serum tryptase levels in melanoma patients : case-control study and review of the literature. In: Giornale Italiano di Dermatologia e Venereologia. 2017.
@article{34db459d806d4561b0ca186ddd7441fe,
title = "Serum tryptase levels in melanoma patients: case-control study and review of the literature",
abstract = "BACKGROUND: Serum tryptase results from the constant release of the enzyme from mast cells and serum tryptase levels are commonly considered to be related to the total number of mast cells. They are increased in several malignancies, as pancreatic carcinoma, angiosarcoma, hepatic carcinoma and proliferative and/or non- proliferative hematological disorders. Contrariwise, it has been reported that the number of tryptase+ and chymase+ mast cells was lower in deeply invasive melanoma compared to in-situ melanoma and dysplastic nevi. Considering the underlying pathophysiological linkages between mast cells and melanocytes and that serum tryptase is related to angiogenesis, tissue-degrading proprieties and metastatization, we have decided to evaluate serum tryptase levels in melanoma patients and in a healthy control.METHODS: We performed a case-control study evaluating serum tryptase in melanoma and in healthy group. Starting from an initial general analysis, we have performed a sub-analysis for each sample.RESULTS: In general population serum tryptase was statistically higher in elderly patients. Generally, in melanoma patients, median serum tryptase was in lower normal range. We found a decreasing of serum tryptase levels from the healthy control to thin (≤ 1.00 mm Breslow thickness), reaching the lowest levels in thicker melanoma (≥ 1.01 m Breslow thickness), in ulcerated and metastatic melanoma.CONCLUSION: Tryptase may have a protective role in melanoma or, conversely, it may play a role in the early stage of the tumorigenesis. Serum tryptase is an easy and useful biomarker to better investigate melanoma biology.",
author = "Giovanni Paolino and Elisa Moliterni and Dario Didona and Michele Cardone and Teresa Lopez and Valentina Garelli and Richetta, {Antonio G} and Ugo Bottoni and Carmen Cantisani and Alfredo Rossi and Stefano Calvieri",
year = "2017",
month = "1",
day = "12",
doi = "10.23736/S0392-0488.17.05524-9",
language = "English",
journal = "Giornale Italiano di Dermatologia e Venereologia",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",

}

TY - JOUR

T1 - Serum tryptase levels in melanoma patients

T2 - case-control study and review of the literature

AU - Paolino, Giovanni

AU - Moliterni, Elisa

AU - Didona, Dario

AU - Cardone, Michele

AU - Lopez, Teresa

AU - Garelli, Valentina

AU - Richetta, Antonio G

AU - Bottoni, Ugo

AU - Cantisani, Carmen

AU - Rossi, Alfredo

AU - Calvieri, Stefano

PY - 2017/1/12

Y1 - 2017/1/12

N2 - BACKGROUND: Serum tryptase results from the constant release of the enzyme from mast cells and serum tryptase levels are commonly considered to be related to the total number of mast cells. They are increased in several malignancies, as pancreatic carcinoma, angiosarcoma, hepatic carcinoma and proliferative and/or non- proliferative hematological disorders. Contrariwise, it has been reported that the number of tryptase+ and chymase+ mast cells was lower in deeply invasive melanoma compared to in-situ melanoma and dysplastic nevi. Considering the underlying pathophysiological linkages between mast cells and melanocytes and that serum tryptase is related to angiogenesis, tissue-degrading proprieties and metastatization, we have decided to evaluate serum tryptase levels in melanoma patients and in a healthy control.METHODS: We performed a case-control study evaluating serum tryptase in melanoma and in healthy group. Starting from an initial general analysis, we have performed a sub-analysis for each sample.RESULTS: In general population serum tryptase was statistically higher in elderly patients. Generally, in melanoma patients, median serum tryptase was in lower normal range. We found a decreasing of serum tryptase levels from the healthy control to thin (≤ 1.00 mm Breslow thickness), reaching the lowest levels in thicker melanoma (≥ 1.01 m Breslow thickness), in ulcerated and metastatic melanoma.CONCLUSION: Tryptase may have a protective role in melanoma or, conversely, it may play a role in the early stage of the tumorigenesis. Serum tryptase is an easy and useful biomarker to better investigate melanoma biology.

AB - BACKGROUND: Serum tryptase results from the constant release of the enzyme from mast cells and serum tryptase levels are commonly considered to be related to the total number of mast cells. They are increased in several malignancies, as pancreatic carcinoma, angiosarcoma, hepatic carcinoma and proliferative and/or non- proliferative hematological disorders. Contrariwise, it has been reported that the number of tryptase+ and chymase+ mast cells was lower in deeply invasive melanoma compared to in-situ melanoma and dysplastic nevi. Considering the underlying pathophysiological linkages between mast cells and melanocytes and that serum tryptase is related to angiogenesis, tissue-degrading proprieties and metastatization, we have decided to evaluate serum tryptase levels in melanoma patients and in a healthy control.METHODS: We performed a case-control study evaluating serum tryptase in melanoma and in healthy group. Starting from an initial general analysis, we have performed a sub-analysis for each sample.RESULTS: In general population serum tryptase was statistically higher in elderly patients. Generally, in melanoma patients, median serum tryptase was in lower normal range. We found a decreasing of serum tryptase levels from the healthy control to thin (≤ 1.00 mm Breslow thickness), reaching the lowest levels in thicker melanoma (≥ 1.01 m Breslow thickness), in ulcerated and metastatic melanoma.CONCLUSION: Tryptase may have a protective role in melanoma or, conversely, it may play a role in the early stage of the tumorigenesis. Serum tryptase is an easy and useful biomarker to better investigate melanoma biology.

U2 - 10.23736/S0392-0488.17.05524-9

DO - 10.23736/S0392-0488.17.05524-9

M3 - Article

JO - Giornale Italiano di Dermatologia e Venereologia

JF - Giornale Italiano di Dermatologia e Venereologia

SN - 0392-0488

ER -